NasdaqGS:JAZZPharmaceuticals
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing
Jazz Pharmaceuticals (NasdaqGS:JAZZ) is back in focus after practice changing HERIZON GEA trial results and plans to file a supplemental Biologics License Application in 2026 for first line gastroesophageal adenocarcinoma therapies.
See our latest analysis for Jazz Pharmaceuticals.
Investors have responded positively to the HERIZON GEA update, with a 24.26% 90 day share price return from Jazz Pharmaceuticals and a 37.58% 1 year total shareholder return, suggesting momentum has picked up...